Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

Breast Cancer Research and Treatment

Volumn 104, Issue 1, 2007, Pages 1-11

  Mohanty, Kartik ^a   Saha, Asim ^a   Pal, Smarajit ^a   Mallick, Palash ^a   Chatterjee, Sunil K ^a   Foon, Kenneth A ^b   Bhattacharya Chatterjee, Malaya ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anti idiotype antibody; Breast cancer; Her 2 neu; Murine model; Vaccines

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTISERUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FREUND ADJUVANT; HEMOCYANIN; QS 21; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; RECEPTOR, ERBB-2;

EID: 34250843855     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9391-9     Document Type: Article

References (54)

1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
2. Natali PG, Nicotra MR, Bigotti A et al (1990) Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45:457-461
3. Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
4. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
5. van de Vijver MJ, Peterse JL, Mooi WJ et al (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245
6. Berchuck A, Kamel A, Whitaker R et al (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091
7. Berchuck A, Rodriguez G, Kinney RB et al (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15-21
8. Kern JA, Schwartz DA, Nordberg JE et al (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5187
9. Ward RL, Hawkins NJ, Coomber D et al (1999) Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 60:510-515
10. Press MF, Bernstein L, Thomas PA et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904
11. Niehans GA, Singleton TP, Dykoski D et al (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230-1235
12. Peoples GE, Goedegebuure PS, Smith R et al (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436
13. Knutson KL, Schiffman K, Cheever MA et al (2002) Immunization of cancer patients with a HER-2/neu HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014-1018
14. Disis ML, Gooley TA, Rinn K et al (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632
15. Ikuta Y, Katayama N, Wang L et al (2002) Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99:3717-3724
16. Chen Y, Hu D, Eling DJ et al (1998) DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 58:1965-1971
17. Rovero S, Amici A, Carlo ED et al (2000) DNA vaccination against rat her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133-5142
18. Riethmuller G, Holz E, Schlimok G et al (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788-1794
19. Ohnishi Y, Nakamura H, Yoshimura M et al (1995) Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. Br J Cancer 71:969-973
20. Stockmeyer B, Valerius T, Repp R et al (1997) Preclinical studies with Fc(γ)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696-701
21. Brodowicz T, Kandioler D, Tomek S et al (2001) Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 85:1764-1770
22. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783-792
23. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
24. Lindenmann J (1973) Speculations on idiotypes of homebodies. Ann Immunol (Paris) 124:171-184
25. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373-389
26. Bhattacharya-Chatterjee M, Köhler H (1989) Anti-idiotype tumor vaccines. Adv Exp Med Biol 251:113-127
27. Bhattacharya-Chatterjee M, Baral RN, Chatterjee SK et al (2000) Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 49:133-141
28. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA (2000) Anti-idiotype vaccine against cancer. Immunol Lett 74:51-58
29. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA (2002) Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2:869-881
30. Pal S, Mohanty K, Chatterjee SK et al (2003) Generation of anti-idiotypic antibody vaccine mimicking human HER2/Neu. Proc Am Assoc Cancer Res 44:196
31. Penichet ML, Challita PM, Shin SU et al (1999) In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 49:179-188
32. Sen G, Chakraborty M, Foon KA et al (1997) Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res 3:1969-1976
33. Campbell MJ, Carroll W, Kon S et al (1987) Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139:2825-2833
34. Kensil CR, Patel U, Lennick M et al (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146:431-437
35. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M et al (1997) Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 57:728-734
36. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
37. Ragupathi G, Meyers M, Adluri S et al (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659-666
38. Lewis JJ, Janetzki S, Schaed S et al (2000) Evaluation of CD8(+) T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 87:391-398
39. Foon KA, John WJ, Chakraborty M et al (1999) Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17:2889-2895
40. Foon KA, John WJ, Chakraborty M et al (1997) Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 3:1267-1276
41. Foon KA, Sen G, Hutchins L et al (1998) Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4:1117-1124
42. Foon KA, Lutzky J, Baral RN et al (2000) Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18:376-384
43. Cooley S, Burns LJ, Repka T et al (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27:1533-1541
44. Reilly RT, Machiels JP, Emens LA et al (2001) The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880-883
45. Spiridon CI, Ghetie MA, Uhr J et al (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8:1720-1730
46. Somasundaram R, Zaloudik J, Jacob L et al (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 155:3253-3261
47. Chatterjee SK, Tripathi PK, Chakraborty M et al (1998) Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 58:1217-1224
48. Pride MW, Shuey S, Grillo-Lopez A et al (1998) Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimics the high molecular weight proteoglycan antigen. Clin Cancer Res 4:2363-2370
49. Durrant LG, Buckley DJ, Robins RA et al (2000) 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int J Cancer 85:87-92
50. Saha A, Baral RN, Chatterjee SK et al (2006) CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 55:515-527
51. Hung K, Hayashi R, Lafond-Walker A et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368
52. Foy TM, Bannink J, Sutherland RA et al (2001) Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 19:2598-2606
53. Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161:2195-2200
54. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686